Egypt Allergy Therapeutics Market Analysis

Egypt Allergy Therapeutics Market Executive Summary

Egypt Allergy Therapeutics Market was valued at $65 Mn in 2022 and is estimated to reach $119 Mn in 2030, exhibiting a CAGR of 7.9% during the forecast period.

Allergens are environmental substances that can occasionally trigger allergic reactions in the body. Dust mites, pollen, mildew, and specific foods like milk, eggs, soy, and almonds are examples of common allergies. Allergy reactions may appear as a variety of symptoms, ranging from less serious ones like itchy eyes and runny noses to more serious ones like anaphylaxis, which can cause unconsciousness and breathing problems. Immunotherapy, avoiding allergens, and prescription medicines, including nasal corticosteroids and antihistamines, are a few viable treatment options.

The incidence of bronchial asthma among school-age children in Egypt is relatively high, approximately 20.6%, higher than in several other nations. At the same time, 8.7% of Egyptian adults report having a food allergy, with cow's milk, eggs, and peanuts being major culprits. Another common eczema variation in the nation is atopic dermatitis, especially among young people. These prevalence rates are influenced by various causes, including environmental factors like dust mites, pollution, and allergies. A family history of allergies might enhance sensitivity, so genetics also play a part. Furthermore, dietary patterns and lifestyle choices are recognized as possible factors that could impact the occurrence of allergies.

GlaxoSmithKline and Cairo pharmacies launched a trial program in August 2023 to provide free consultations and digital health solutions for people with respiratory allergies. GSK's commitment to improving patient interaction and providing tailored treatment is demonstrated by this calculated decision.

Pharmedia announced in September 2023 that it would be increasing its production capacity for nasal corticosteroids and antihistamines in response to the rising demand for allergy treatments in Egypt. Pharmedia aims to demonstrate its dedication to strengthening local production capacities and growing its market share in Egypt while simultaneously lowering the cost and increasing the availability of allergy medications in the nation.

Market Dynamics

Market Growth Drivers

Rising Incidence of Allergies: Allergies affect a large percentage of Egyptians, especially those with respiratory conditions like asthma and allergic rhinitis. Factors such as dust mites, shifting food habits, and pollution in the environment may be contributing to the rising incidence of these illnesses.

Shifting Treatment Trends: There may be new markets for customized allergy treatment options due to the growing need for individualized medical plans that are based on each patient's needs and triggers. The increased use of telehealth platforms makes it easier to access doctors and prescription drugs, which drives market growth.

Urbanization and Changing Lifestyles: Urbanization and changes in lifestyle, such as increased exposure to indoor allergens such dust mites and outdoor pollutants, are major factors driving the trend toward a growing demand for allergy treatment medications.

Market Restraints

Regulatory Challenges: Pharmaceutical companies find it difficult and time-consuming to navigate the regulatory environment for the importation and registration of novel allergy therapies. As it delays the timely introduction of novel therapeutic alternatives, this complexity may limit market growth.

High Cost of Treatment: Treatments for allergies can be quite expensive for certain patients, particularly if they involve allergen immunotherapy methods such as immunotherapy injections and SLIT tablets. Allergy drugs high cost may prohibit people from using and accessing them broadly, which would restrict their market penetration.

Treatment Compliance and Adherence: For allergy medications, especially immunotherapy therapies, to be effective, patients must adhere to lengthy treatment plans. Obstacles like high prices, complexity, or poor outcomes resulting in poor patient adherence may reduce the effectiveness of treatment and prevent the market from growing.

Healthcare Policies and Regulatory Landscape

The Egyptian Drug Authority (EDA), which operates under the Ministry of Health and Population, is principally in charge of managing drug regulations and healthcare policies in Egypt. In order to guarantee the quality, safety, and efficacy of medications on the market, the EDA is in charge of overseeing and regulating the pharmaceutical industry. Standards for drug registration, manufacturing procedures, and importation are established and upheld by it. The EDA's regulatory standards must be followed by pharmaceutical businesses that want to promote their current products or introduce new ones. This includes following Good Manufacturing Practices (GMP), completing clinical trials, and providing thorough documentation. Protecting public health, facilitating access to high-quality drugs, and fostering the expansion of Egypt's pharmaceutical sector are the three main objectives of the regulatory framework.

Competitive Landscape

Key Players

• Novartis
• Sanofi
• Johnson & Johnson
• GlaxoSmithKline
• Pfizer
• Merck & Co.
• Bayer
• AstraZeneca
• Roche
• Teva Pharmaceutical Industries